

Molecular Basis of
**Neurological
Disease**
October 23-24, 2006
Philadelphia, PA

Last Name First Name M.I./Degree

Email

Affiliation Specialty

Address

City State Zip

Telephone Facsimile

Please Select from the following:

- Lunch: October 23 I will attend will not attend
Lunch: October 24 I will attend will not attend



Please register by October 9, 2006.

Mail to: Thomas Jefferson University, OIES
1020 Locust Street, M70
Philadelphia, PA 19107-6799
Attn: EMC

or Fax: 215-503-2873 Attn: EMC

If you have any special needs, please contact our office by
September 22, 2006 at 215-503-4335.

**Lennox K. Black International
Prize for Excellence in Medicine**
4th Symposium



Molecular Basis of
**Neurological
Disease**

October 23-24, 2006

Thomas Jefferson University
Philadelphia, PA

Sponsored by Thomas Jefferson University,
with support from Forest Laboratories



The Lennox K. Black International Prize for Excellence in Medicine has been awarded to Prof. Colin Masters of The University of Melbourne and Prof. Konrad Beyreuther of The University of Heidelberg. Prof. Beyreuther and Prof. Masters will be the keynote speakers at the Symposium, *Molecular Basis of Neurological Disease*.

This symposium is sponsored by Thomas Jefferson University and made possible through the generous support of Mr. Lennox K. Black, Emeritus Trustee of the University.

The Prize recognizes the importance of international communication in scientific discovery and the advance of medicine. The Prize is designed to bring global leaders in biomedical research to Jefferson to foster their interaction with faculty experts, and is a major contribution to Jefferson's overall global initiative, which encourages the exchange of ideas and information between nations in the service of medical research, education, and clinical care.

Keynote Speakers

Colin L Masters, MD
*Laureate Professor
Department of Pathology
School of Medicine
The University of Melbourne
Australia*

Konrad Beyreuther, PhD
*Professor and Director
Institute for Molecular Biology
University of Heidelberg*

Invited Speakers

Josep Dalmau, MD, PhD
*University of Pennsylvania
School of Medicine*

Steve A. N. Goldstein, MD, PhD
*University of Chicago and
Pritzker School of Medicine*

John W. Griffin, MD
The Johns Hopkins Hospital

William F. Hickey, MD
Dartmouth Medical School

C. David James, PhD
The Mayo Clinic

Daniel Johnston, PhD
University of Texas at Austin

Virginia Lee, PhD
*University of Pennsylvania
School of Medicine*

**Local Organizing
Committee**

Sam Gandy, MD, PhD, *Chair*
David Andrews, MD
Manuel Covarrubias, MD, PhD
Laura Gitlin, PhD
James H. Keen, PhD
Diane Merry, PhD
A. M. Rostami, MD, PhD
Matthias Schnell, PhD

Robert P. Lisak, MD
Wayne State University

Linda Liao, MD, PhD
*University of California
Los Angeles*

Chester A. Mathis, PhD
University of Pittsburgh

Bruce McEwen, PhD
The Rockefeller University

Donald W. Pfaff, PhD
The Rockefeller University

Susan Weiss, PhD
*University of Pennsylvania
School of Medicine*

John Zeisel, PhD
Hearthstone Alzheimer Care

Session Topics

- Channelopathies
- Neurodegeneration
- Neurobiology of Stress & Gonadal Hormone Action
- Neuro-oncology
- Neurovirology & Neuroimmunology

Call for Posters

In addition to invited speakers, poster presentations will be chosen from submitted abstracts. Abstracts are invited on all aspects of the Molecular Basis of Neurological Disease and must be submitted by the **September 30 deadline**. Submitted abstracts will be reviewed by the Scientific Program Committee. Notification of acceptance will be sent to you by email.

Abstract Format

- Abstracts should be submitted in Adobe Portable Document Format (.pdf).
- The abstract should fit within a rectangle 6"x9".
- The abstract length is not to exceed ONE page.
- The text should be left justified and single-spaced with character size set to 12 point, and a Times New Roman font selected.
- The title should be typed in CAPITAL and **BOLD**.
- The authors' names should appear on a new line immediately beneath the title, with the presenting author's name underlined.
- The authors' affiliations should be placed on a separate line immediately beneath the authors' names.
- The abstract should introduce the purpose of the study, summarize the methods, present the results and discuss major conclusions.

ABSTRACT DEADLINE is September 30, 2006

Send by Email to:

Erin.Cupp@jefferson.edu

For more information, visit our web site at
www.Jefferson.edu/oies/symposium

Molecular Basis of Neurological Disease

October 23-24, 2006
Philadelphia, PA

Monday, October 23, 2006

- 8:00 am **Registration Opens – Continental Breakfast**
- 8:45 am **Welcoming Remarks**
James H. Keen, PhD
Dean, Jefferson College of Graduate Studies
Sam Gandy, MD, PhD
Director, Farber Institute for Neurosciences
- 8:50 am **Session 1: Channelopathies**
Session Chair:
Manuel Covarrubias, MD, PhD
Session Speakers:
Daniel Johnston, PhD
Steve Goldstein, MD, PhD
- 9:55 am **Break**
- 10:15 am **Basic & Clinical Science of Neurodegeneration**
Session Chair:
Diane Merry, PhD
Session Speakers:
Virginia Lee, PhD
Chester Mathis, PhD
- 11:35 am **Lunch (provided – pre-registration required)**
Poster Session
- 1:00 pm **Awarding of the Lennox K. Black International Prize for Excellence in Medicine**
James H. Keen, PhD
Introduction of Prof. Colin Masters
Sam Gandy, MD, PhD
- 1:05 pm **Keynote Speaker and 2006 Prize Laureate**
Colin L. Masters, MD
- 2:05 pm **Introduction of Prof. Konrad Beyreuther**
Sam Gandy, MD, PhD
- 2:10 pm **Keynote Speaker and 2006 Prize Laureate**
Konrad Beyreuther, PhD

- 3:10 pm **Panel Discussion, Q&A**
- 3:40 pm **Adjourn for Public Session**
- 5:00 pm – **Public Session**
6:30 pm *Janet Reno, 78th Attorney General of the United States*
“A Personal Perspective on Parkinson's Disease”
Colin L. Masters, MD
Konrad Beyreuther, PhD
“Promise of Basic Research for Alzheimer's Care and Prevention”
- 7:30 pm **Dinner for invited speakers and planning committee members**

Tuesday, October 24, 2006

- 8:00 am **Registration Open**
Continental Breakfast
- 8:30 am **Session 3: Neurobiology of Stress & Gonadal Hormone Action**
Session Chair:
Laura Gitlin, PhD
Session Speakers
John Zeisel, PhD
Bruce McEwen, PhD
Donald Pfaff, PhD
- 10:30 am **Break**
- 10:50 am **Session 4: Neuro-oncology**
Session Chair:
David Andrews, MD
Session Speakers:
David James, MD
Linda Liao, MD, PhD
- 12:10 pm **Lunch (provided – preregistration required)**
Poster Session
- 1:30 pm **Session 5: Neurovirology & Neuroimmunology**
Session Chairs:
A. M. Rostami, MD, PhD
Matthias Schnell, PhD
Session Speakers:
Susan Weiss, PhD
Jack Griffin, MD
Josep Dalmau, MD, PhD
- 3:30 pm **Break**
- 3:50 pm **Session 5 (continued)**
Session Speakers:
Robert Lisak, MD
William Hickey, MD
- 5:15 pm **Closing Comments and Adjournment**

Meeting Dates and Place

- The meeting will take place on the campus of Thomas Jefferson University in the Connelly Conference Room of the Bluemle Life Sciences Building, located at 233 South 10th Street, Philadelphia, Pennsylvania. The symposium begins on Monday, October 23, 2006 at 8:45 am and adjourns on Tuesday, October 24, 2006 at 5:15 pm.
- On-site registration will be held **Monday, October 23, 2006** beginning at **8:00 am** in the Lobby of the Bluemle Life Sciences Building, 233 South 10th Street, Philadelphia, PA.
- Continental breakfast and lunch will be provided on both days for pre-registrants of the symposium.
- Posters will be displayed throughout the symposium and authors will be present during the lunch breaks.
- A public session will be held on Monday, October 23, 2006 at 5:00 pm in the Foerderer Auditorium of Thomas Jefferson University, featuring Janet Reno, 78th Attorney General of the United States, speaking on “A Personal and Federal Perspective on Parkinson's Disease.”

Transportation

Philadelphia is easily accessible by train from New York City, Washington DC, and Baltimore. For more information on train travel or train reservations, visit www.Amtrak.com. By car, Thomas Jefferson University is convenient to I-95.

For further information about transportation or directions to Philadelphia, please call **215-503-1232** or visit <https://www.jeffersonhospital.org/patient/article4067.html>

Accommodations

Closest to Thomas Jefferson University are the Doubletree Hotel, Holiday Inn Midtown, Marriott Center City, Alexander Inn and Loews Hotel. For information on these and additional hotels in the Philadelphia area, please refer to www.Philadelphia.about.com/cs/centercityhotels.

**Colin L Masters, B Med Sci (Hons),
MBBS, MD, FRCPath, FRCPA, FAA**

**Konrad Beyreuther, PhD, Prof.
Dr. rer. nat. Dr. med. h.c.**

Colin Masters' and Konrad Beyreuther's achievements have provided a path to the current development of therapeutic strategies for Alzheimer's and other neurodegenerative diseases, affecting the quality of life of millions of people worldwide. They have pioneered studies of the biochemistry of the changes found in the brains of persons dying from Alzheimer's and Creutzfeldt-Jakob diseases.

From their discoveries of the sequence of the A β amyloid protein in the brain plaques of Alzheimer's disease, which facilitated cloning the gene for the amyloid precursor protein and revealed for the first time the proteolytic origin of the A β protein from neurons, they have gone on to elucidate the pathways leading to the accumulation and toxicity of A β in the aging human brain. These pathways have been of great importance in the development of a variety of drug targets, some directed at the secretases that facilitate the release of amyloid A β protein from nerve cells or directed at lipids of the lipid bilayer (especially cholesterol) that control secretase activity, and others directed at the toxicity and aggregation of the A β protein itself. Thus, from a state twenty years ago when virtually nothing was understood about the molecular basis of Alzheimer's disease, the studies of Masters and Beyreuther are widely acknowledged as having had a major influence on the direction of a now worldwide research effort.

The next five years are exceptionally promising with the real prospect of developing new drugs aimed at the A β amyloidogenic pathway (γ - and β -secretase inhibitors; statins; metal protein attenuating compounds or MPACs) and applying pre-clinical diagnosis using A β as the target (PET scans, blood and CSF assays). Their work has also opened up new insights into other major neurodegenerative diseases (such as Creutzfeldt-Jakob and Parkinson's diseases) in which aggregated proteins accumulate, providing clues to therapeutic interventions for multiple disease states.